8e093fcb6aff6aaf…

{
  "id": "NCT00090116",
  "type": "Study",
  "data": {
    "briefSummary": "Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).",
    "completionDate": "2005-03",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "enrollmentCount": 400,
    "enrollmentType": null,
    "nctId": "NCT00090116",
    "phase": "PHASE3",
    "sponsorId": "forest-laboratories",
    "startDate": "2003-03",
    "status": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "title": "A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's Type",
    "url": "https://clinicaltrials.gov/study/NCT00090116"
  }
}